Applications of artificial intelligence in drug development using real-world data.

Journal: Drug discovery today
Published Date:

Abstract

The US Food and Drug Administration (FDA) has been actively promoting the use of real-world data (RWD) in drug development. RWD can generate important real-world evidence reflecting the real-world clinical environment where the treatments are used. Meanwhile, artificial intelligence (AI), especially machine- and deep-learning (ML/DL) methods, have been increasingly used across many stages of the drug development process. Advancements in AI have also provided new strategies to analyze large, multidimensional RWD. Thus, we conducted a rapid review of articles from the past 20 years, to provide an overview of the drug development studies that use both AI and RWD. We found that the most popular applications were adverse event detection, trial recruitment, and drug repurposing. Here, we also discuss current research gaps and future opportunities.

Authors

  • Zhaoyi Chen
    Department of Epidemiology, College of Medicine & College of Public Health and Health Professions, University of Florida, Gainesville, FL, USA.
  • Xiong Liu
    AI Innovation Center, Novartis, Cambridge, MA 02142, USA.
  • William Hogan
    Departments of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, Florida, USA.
  • Elizabeth Shenkman
    Department of Health Outcomes & Biomedical Informatics, University of Florida, Gainesville, FL, USA.
  • Jiang Bian
    Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, Florida, United States of America.